• Originator Genentech; Hackensack University Medical Center
• Developer All Ireland Cooperative Oncology Research Group; ARCAGY/GINECO Group; Austrian Breast & Colorectal Cancer Study Group; Bayer; Beth Israel Deaconess Medical Center; Breast Cancer Research Foundation; Brigham and Women's Hospital; Bristol-Myers Squibb; Cancer and Leukemia Group B; Cancer Research UK; Chugai Pharmaceutical; Cincinnati Children's Hospital Medical Center; Dana-Farber Cancer Institute; Duke University; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; Genentech; Hackensack University Medical Center; Hoosier Cancer Research Network; Indiana University School of Medicine; Japan Breast Cancer Research Group; M. D. Anderson Cancer Center; Massachusetts General Hospital; Melanoma Research Foundation Breakthrough Consortium; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); National Comprehensive Cancer Network; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Norwegian Radium Hospital; NSABP Foundation; Ohio State University Medical Center; Peter MacCallum Cancer Centre; Roche; Royal Marsden NHS Foundation Trust; Sanofi; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; Servier; South Eastern European Research Oncology Group; Spanish Cooperative Group for Digestive Tumour Therapy; Spanish Lung Cancer Group; Stanford University School of Medicine; SWOG; The Catalan Institute of Oncology; UNICANCER; University College London; University of Alabama at Birmingham; University of Arkansas System; University of California, Davis; University of Iowa; University of Oklahoma; University of Tennessee; University of Texas M. D. Anderson Cancer Center; US Oncology Research; West German Study Group; Xijing Hospital
• Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
• Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors

• Orphan Drug Status

  Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  Yes - Peritoneal cancer; Glioma; Cervical cancer; Ovarian cancer; Fallopian tube cancer; Mesothelioma; Renal cell carcinoma
• New Molecular Entity Yes

Highest Development Phases

• Marketed Breast cancer; Cervical cancer; Colorectal cancer; Glioblastoma; Glioma; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
• Registered Fallopian tube cancer; Peritoneal cancer
• Phase III Head and neck cancer; Malignant-mesothelioma; Small cell lung cancer
• Phase II/III Malignant melanoma
• Phase II Biliary cancer; Brain metastases; Endometrial cancer; Ewing's sarcoma; Gastric cancer; Gynaecological cancer; Hodgkin's disease; Intestinal cancer; Liver metastases; Meningioma; Multiple myeloma; Neuroblastoma; Neurofibromatosis 1; Rectal cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
• Phase I/II Neoplastic meningitis; Sarcoma
• Suspended Carcinoid tumour
• Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Eye disorders; Gastrointestinal stromal tumours; Oesophageal cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

• 13 May 2025 The Massachusetts General Hospital terminates a phase I/II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA due to slow accrual (NCT02521051)
• 22 Apr 2025 Roche terminates the phase IIIb ATHECA trial for Liver cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Spain (IV, Infusion), the trial was completed as planned and terminated only for participants with over 24 months of follow-up, per protocol (NCT04732286)
• 27 Feb 2025 Roche plans a phase III trial in Small cell lung cancer (First line therapy, Combination therapy) in Japan and China (IV) in 2026 (Chugai Pharmaceutical pipeline, February 2025)